Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT03569293




Registration number
NCT03569293
Ethics application status
Date submitted
14/06/2018
Date registered
26/06/2018
Date last updated
5/03/2024

Titles & IDs
Public title
Evaluation of Upadacitinib in Adolescent and Adult Patients With Moderate to Severe Atopic Dermatitis (Eczema)
Scientific title
A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Adolescent and Adult Subjects With Moderate to Severe Atopic Dermatitis
Secondary ID [1] 0 0
2022-502938-30-00
Secondary ID [2] 0 0
M16-045
Universal Trial Number (UTN)
Trial acronym
Measure Up 1
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Atopic Dermatitis 0 0
Condition category
Condition code
Skin 0 0 0 0
Dermatological conditions
Skin 0 0 0 0
Other skin conditions
Inflammatory and Immune System 0 0 0 0
Other inflammatory or immune system disorders

Intervention/exposure
Study type
Interventional(has expanded access)
Description of intervention(s) / exposure
Treatment: Drugs - Placebo for Upadacitinib
Treatment: Drugs - Upadacitinib

Placebo comparator: Placebo / Upadacitinib - Participants will receive placebo orally once a day (QD) for 16 weeks in the double-blind treatment period. At Week 16 participants will be re-randomized to receive either upadacitinib 15 mg or upadacitinib 30 mg QD up to Week 260.

Experimental: Upadacitinib 15 mg QD - Participants will receive upadacitinib 15 mg orally once a day for up to 260 weeks.

Experimental: Upadacitinib 30 mg QD - Participants will receive upadacitinib 30 mg orally once a day for up to 260 weeks.


Treatment: Drugs: Placebo for Upadacitinib
Tablets taken orally once a day

Treatment: Drugs: Upadacitinib
Tablets taken orally once a day
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16
Timepoint [1] 0 0
Baseline and Week 16
Primary outcome [2] 0 0
Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of = 2 Points at Week 16
Timepoint [2] 0 0
Baseline and Week 16
Secondary outcome [1] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus Numerical Rating Scale (NRS) at Week 16
Timepoint [1] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [2] 0 0
Main Study: Percentage of Participants Achieving a 90% Reduction From Baseline in EASI Score (EASI 90) at Week 16
Timepoint [2] 0 0
Baseline and Week 16
Secondary outcome [3] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 4
Timepoint [3] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 4
Secondary outcome [4] 0 0
Main Study: Percentage of Participants Achieving an EASI 75 Response at Week 2
Timepoint [4] 0 0
Baseline and Week 2
Secondary outcome [5] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 1
Timepoint [5] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 1
Secondary outcome [6] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Day 2
Timepoint [6] 0 0
Baseline and Day 2
Secondary outcome [7] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Day 3
Timepoint [7] 0 0
Baseline and Day 3
Secondary outcome [8] 0 0
Main Study: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
Timepoint [8] 0 0
From first dose of study drug to Week 16
Secondary outcome [9] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 12 Points From Baseline in Atopic Dermatitis Impact Scale (ADerm-IS) Sleep Domain Score at Week 16
Timepoint [9] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [10] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Atopic Dermatitis Symptom Scale (ADerm-SS) Skin Pain Score at Week 16
Timepoint [10] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [11] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 28 Points From Baseline in ADerm-SS 7-Item Total Symptom Score (TSS-7) at Week 16
Timepoint [11] 0 0
Baseline and Week 16
Secondary outcome [12] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
Timepoint [12] 0 0
Baseline and Week 16
Secondary outcome [13] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 14 Points From Baseline in in ADerm-IS Daily Activities Domain Score at Week 16
Timepoint [13] 0 0
Baseline and Week 16
Secondary outcome [14] 0 0
Main Study: Percentage of Participants Achieving a 100% Reduction From Baseline in EASI Score (EASI 100) at Week 16
Timepoint [14] 0 0
Baseline and Week 16
Secondary outcome [15] 0 0
Main Study: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Timepoint [15] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [16] 0 0
Main Study: Percent Change From Baseline in EASI Score at Week 16
Timepoint [16] 0 0
Baseline and Week 16
Secondary outcome [17] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Patient Oriented Eczema Measure (POEM) Total Score at Week 16
Timepoint [17] 0 0
Baseline and Week 16
Secondary outcome [18] 0 0
Main Study: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Dermatology Life Quality Index (DLQI) at Week 16
Timepoint [18] 0 0
Baseline and Week 16
Secondary outcome [19] 0 0
Main Study: Percent Change From Baseline in Scoring Atopic Dermatitis (SCORAD) Score at Week 16
Timepoint [19] 0 0
Baseline and Week 16
Secondary outcome [20] 0 0
Main Study: Percentage of Participants Achieving a Hospital Anxiety and Depression Scale-Anxiety (HADS-A) Score and Hospital Anxiety and Depression Scale-Depression (HADS-D) Score of < 8 at Week 16
Timepoint [20] 0 0
Baseline and Week 16
Secondary outcome [21] 0 0
Main Study: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
Timepoint [21] 0 0
Week 16
Secondary outcome [22] 0 0
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 16
Timepoint [22] 0 0
Baseline and Week 16
Secondary outcome [23] 0 0
Adolescents: Percentage of Participants Achieving a vIGA-AD of 0 or 1 With a Reduction From Baseline of = 2 Points at Week 16
Timepoint [23] 0 0
Baseline and Week 16
Secondary outcome [24] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 16
Timepoint [24] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [25] 0 0
Adolescents: Percentage of Participants Achieving an EASI 90 Response at Week 16
Timepoint [25] 0 0
Baseline and Week 16
Secondary outcome [26] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 4
Timepoint [26] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 4
Secondary outcome [27] 0 0
Adolescents: Percentage of Participants Achieving an EASI 75 Response at Week 2
Timepoint [27] 0 0
Baseline and Week 2
Secondary outcome [28] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Week 1
Timepoint [28] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 1
Secondary outcome [29] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Day 2
Timepoint [29] 0 0
Baseline and Day 2
Secondary outcome [30] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in Worst Pruritus NRS at Day 3
Timepoint [30] 0 0
Baseline and Day 3
Secondary outcome [31] 0 0
Adolescents: Percentage of Participants Experiencing a Flare During the Double-blind Treatment Period
Timepoint [31] 0 0
From first dose of study drug to Week 16
Secondary outcome [32] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 12 Points From Baseline in ADerm-IS Sleep Domain Score at Week 16
Timepoint [32] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [33] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in ADerm-SS Skin Pain Score at Week 16
Timepoint [33] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [34] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 28 Points From Baseline in ADerm-SS TSS-7 at Week 16
Timepoint [34] 0 0
Baseline and Week 16
Secondary outcome [35] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 11 Points From Baseline in ADerm-IS Emotional State Domain Score at Week 16
Timepoint [35] 0 0
Baseline and Week 16
Secondary outcome [36] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 14 Points From Baseline in ADerm-IS Daily Activities Domain Score at Week 16
Timepoint [36] 0 0
Baseline and Week 16
Secondary outcome [37] 0 0
Adolescents: Percentage of Participants Achieving an EASI 100 Response at Week 16
Timepoint [37] 0 0
Baseline and Week 16
Secondary outcome [38] 0 0
Adolescents: Percent Change From Baseline in Worst Pruritus NRS at Week 16
Timepoint [38] 0 0
Baseline (last available rolling average before the first dose of study drug) and Week 16
Secondary outcome [39] 0 0
Adolescents: Percent Change From Baseline in EASI Score at Week 16
Timepoint [39] 0 0
Baseline and Week 16
Secondary outcome [40] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in POEM Total Score at Week 16
Timepoint [40] 0 0
Baseline and Week 16
Secondary outcome [41] 0 0
Adolescents: Percentage of Participants Achieving a Reduction of = 4 Points From Baseline in DLQI Score at Week 16
Timepoint [41] 0 0
Baseline and Week 16
Secondary outcome [42] 0 0
Adolescents: Percent Change From Baseline in SCORAD Score at Week 16
Timepoint [42] 0 0
Baseline and Week 16
Secondary outcome [43] 0 0
Adolescents: Percentage of Participants Achieving HADS-A Score and HADS-D Score of < 8 at Week 16
Timepoint [43] 0 0
Baseline and Week 16
Secondary outcome [44] 0 0
Adolescents: Percentage of Participants Achieving a DLQI Score of 0 or 1 at Week 16
Timepoint [44] 0 0
Baseline and Week 16

Eligibility
Key inclusion criteria
* Body weight of = 40 kg at Baseline Visit for participants between = 12 and < 18 years of age
* Chronic atopic dermatitis (AD) with onset of symptoms at least 3 years before Baseline Visit and subject meets Hanifin and Rajka criteria.
* Active moderate to severe AD defined by:

* Eczema Area and Severity Index (EASI) score = 16 at the Screening and Baseline Visits;
* Validated Investigator's Global Assessment (vIGA) score = 3 at the Screening and Baseline Visits;
* = 10% Body surface area (BSA) of AD involvement at the Screening and Baseline Visits;
* Baseline weekly average of daily Worst Pruritus NRS = 4.
* Candidate for systemic therapy or have recently required systemic therapy for AD
* Subject has applied a topical emollient (moisturizer) twice daily for at least 7 days before the Baseline Visit.
* Documented history of inadequate response to topical corticosteroids (TCS) or topical calcineurin inhibitor (TCI) or documented systemic treatment for AD within 6 months before Baseline Visit
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Prior exposure to any Janus kinase (JAK) inhibitor
* Unable or unwilling to discontinue current atopic dermatitis treatments prior to the study
* Requirement of prohibited medications during the study
* Other active skin diseases or skin infections requiring systemic treatment or would interfere with appropriate assessment of atopic dermatitis lesions
* Female subject who is pregnant, breastfeeding, or considering pregnancy during the study

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
13/08/2018
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
9/10/2025
Actual
Sample size
Target
Accrual to date
Final
912
Recruitment in Australia
Recruitment state(s)
ACT,NSW,SA,VIC,WA
Recruitment hospital [1] 0 0
Woden Dermatology /ID# 205799 - Phillip
Recruitment hospital [2] 0 0
Holdsworth House Medical Practice /ID# 211236 - Darlinghurst
Recruitment hospital [3] 0 0
North Eastern Health Specialists /ID# 205802 - Hectorville
Recruitment hospital [4] 0 0
Skin Health Institute Inc /ID# 204791 - Carlton
Recruitment hospital [5] 0 0
Fremantle Dermatology /ID# 205305 - Fremantle
Recruitment postcode(s) [1] 0 0
2606 - Phillip
Recruitment postcode(s) [2] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [3] 0 0
5073 - Hectorville
Recruitment postcode(s) [4] 0 0
3053 - Carlton
Recruitment postcode(s) [5] 0 0
6160 - Fremantle
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
District of Columbia
Country [5] 0 0
United States of America
State/province [5] 0 0
Florida
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Indiana
Country [8] 0 0
United States of America
State/province [8] 0 0
Louisiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Massachusetts
Country [10] 0 0
United States of America
State/province [10] 0 0
Michigan
Country [11] 0 0
United States of America
State/province [11] 0 0
Missouri
Country [12] 0 0
United States of America
State/province [12] 0 0
Nebraska
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Hampshire
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
Ohio
Country [17] 0 0
United States of America
State/province [17] 0 0
Oklahoma
Country [18] 0 0
United States of America
State/province [18] 0 0
Oregon
Country [19] 0 0
United States of America
State/province [19] 0 0
Pennsylvania
Country [20] 0 0
United States of America
State/province [20] 0 0
Rhode Island
Country [21] 0 0
United States of America
State/province [21] 0 0
South Carolina
Country [22] 0 0
United States of America
State/province [22] 0 0
Texas
Country [23] 0 0
United States of America
State/province [23] 0 0
Washington
Country [24] 0 0
Argentina
State/province [24] 0 0
Buenos Aires
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciuadad Autonoma De Buenos Aires
Country [26] 0 0
Bosnia and Herzegovina
State/province [26] 0 0
Republika Srpska
Country [27] 0 0
Bosnia and Herzegovina
State/province [27] 0 0
Sarajevo
Country [28] 0 0
Bulgaria
State/province [28] 0 0
Sofia
Country [29] 0 0
Bulgaria
State/province [29] 0 0
Pleven
Country [30] 0 0
Bulgaria
State/province [30] 0 0
Stara Zagora
Country [31] 0 0
Canada
State/province [31] 0 0
Alberta
Country [32] 0 0
Canada
State/province [32] 0 0
British Columbia
Country [33] 0 0
Canada
State/province [33] 0 0
Manitoba
Country [34] 0 0
Canada
State/province [34] 0 0
New Brunswick
Country [35] 0 0
Canada
State/province [35] 0 0
Newfoundland and Labrador
Country [36] 0 0
Canada
State/province [36] 0 0
Ontario
Country [37] 0 0
Canada
State/province [37] 0 0
Quebec
Country [38] 0 0
China
State/province [38] 0 0
Beijing
Country [39] 0 0
China
State/province [39] 0 0
Guangdong
Country [40] 0 0
China
State/province [40] 0 0
Liaoning
Country [41] 0 0
China
State/province [41] 0 0
Shanghai
Country [42] 0 0
China
State/province [42] 0 0
Zhejiang
Country [43] 0 0
China
State/province [43] 0 0
Wuhan
Country [44] 0 0
Colombia
State/province [44] 0 0
Antioquia
Country [45] 0 0
Colombia
State/province [45] 0 0
Atlantico
Country [46] 0 0
Colombia
State/province [46] 0 0
Cordoba
Country [47] 0 0
Croatia
State/province [47] 0 0
Grad Zagreb
Country [48] 0 0
Croatia
State/province [48] 0 0
Osjecko-baranjska Zupanija
Country [49] 0 0
Croatia
State/province [49] 0 0
Primorsko-goranska Zupanija
Country [50] 0 0
Croatia
State/province [50] 0 0
Splitsko-dalmatinska Zupanija
Country [51] 0 0
Denmark
State/province [51] 0 0
Hovedstaden
Country [52] 0 0
Denmark
State/province [52] 0 0
Midtjylland
Country [53] 0 0
Estonia
State/province [53] 0 0
Harjumaa
Country [54] 0 0
Estonia
State/province [54] 0 0
Tartumaa
Country [55] 0 0
Finland
State/province [55] 0 0
Varsinais-Suomi
Country [56] 0 0
Finland
State/province [56] 0 0
Kuopio
Country [57] 0 0
Finland
State/province [57] 0 0
Tampere
Country [58] 0 0
France
State/province [58] 0 0
Auvergne-Rhone-Alpes
Country [59] 0 0
France
State/province [59] 0 0
Pays-de-la-Loire
Country [60] 0 0
France
State/province [60] 0 0
Sarthe
Country [61] 0 0
France
State/province [61] 0 0
Lille Cedex
Country [62] 0 0
France
State/province [62] 0 0
Martigues
Country [63] 0 0
France
State/province [63] 0 0
Paris
Country [64] 0 0
France
State/province [64] 0 0
Rouen
Country [65] 0 0
France
State/province [65] 0 0
Toulouse
Country [66] 0 0
Germany
State/province [66] 0 0
Bayern
Country [67] 0 0
Germany
State/province [67] 0 0
Hessen
Country [68] 0 0
Germany
State/province [68] 0 0
Nordrhein-Westfalen
Country [69] 0 0
Germany
State/province [69] 0 0
Rheinland-Pfalz
Country [70] 0 0
Germany
State/province [70] 0 0
Schleswig-Holstein
Country [71] 0 0
Germany
State/province [71] 0 0
Bonn
Country [72] 0 0
Germany
State/province [72] 0 0
Hamburg
Country [73] 0 0
Germany
State/province [73] 0 0
Hannover
Country [74] 0 0
Germany
State/province [74] 0 0
Mainz
Country [75] 0 0
Italy
State/province [75] 0 0
Roma
Country [76] 0 0
Italy
State/province [76] 0 0
Ancona
Country [77] 0 0
Italy
State/province [77] 0 0
Bologna
Country [78] 0 0
Italy
State/province [78] 0 0
Catania
Country [79] 0 0
Italy
State/province [79] 0 0
Napoli
Country [80] 0 0
Italy
State/province [80] 0 0
Pisa
Country [81] 0 0
Japan
State/province [81] 0 0
Aichi
Country [82] 0 0
Japan
State/province [82] 0 0
Fukuoka
Country [83] 0 0
Japan
State/province [83] 0 0
Gifu
Country [84] 0 0
Japan
State/province [84] 0 0
Hokkaido
Country [85] 0 0
Japan
State/province [85] 0 0
Kyoto
Country [86] 0 0
Japan
State/province [86] 0 0
Osaka
Country [87] 0 0
Japan
State/province [87] 0 0
Tokyo
Country [88] 0 0
Japan
State/province [88] 0 0
Yamanashi
Country [89] 0 0
Malaysia
State/province [89] 0 0
Perak
Country [90] 0 0
Malaysia
State/province [90] 0 0
Sabah
Country [91] 0 0
Malaysia
State/province [91] 0 0
Selangor
Country [92] 0 0
New Zealand
State/province [92] 0 0
Hamilton
Country [93] 0 0
Puerto Rico
State/province [93] 0 0
Carolina
Country [94] 0 0
Puerto Rico
State/province [94] 0 0
Ponce
Country [95] 0 0
Puerto Rico
State/province [95] 0 0
San Juan
Country [96] 0 0
Romania
State/province [96] 0 0
Bucuresti
Country [97] 0 0
Romania
State/province [97] 0 0
Cluj Napoca
Country [98] 0 0
Russian Federation
State/province [98] 0 0
Chelyabinskaya Oblast
Country [99] 0 0
Russian Federation
State/province [99] 0 0
Krasnodarskiy Kray
Country [100] 0 0
Russian Federation
State/province [100] 0 0
Saratovskaya Oblast
Country [101] 0 0
Russian Federation
State/province [101] 0 0
Sverdlovskaya Oblast
Country [102] 0 0
Russian Federation
State/province [102] 0 0
Moscow
Country [103] 0 0
Switzerland
State/province [103] 0 0
Basel-Stadt
Country [104] 0 0
Switzerland
State/province [104] 0 0
Geneve
Country [105] 0 0
Switzerland
State/province [105] 0 0
Vaud
Country [106] 0 0
Switzerland
State/province [106] 0 0
Bern
Country [107] 0 0
Turkey
State/province [107] 0 0
Kayseri
Country [108] 0 0
Turkey
State/province [108] 0 0
Ankara
Country [109] 0 0
Turkey
State/province [109] 0 0
Istanbul
Country [110] 0 0
Turkey
State/province [110] 0 0
Yenimahalle
Country [111] 0 0
Ukraine
State/province [111] 0 0
Zaporizka Oblast
Country [112] 0 0
Ukraine
State/province [112] 0 0
Rivne
Country [113] 0 0
United Kingdom
State/province [113] 0 0
London, City Of
Country [114] 0 0
United Kingdom
State/province [114] 0 0
London
Country [115] 0 0
United Kingdom
State/province [115] 0 0
Salford

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
AbbVie
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The objective of this study is to assess the efficacy and safety of upadacitinib for the treatment of adolescent and adult participants with moderate to severe atopic dermatitis (AD) who are candidates for systemic therapy.
Trial website
https://clinicaltrials.gov/study/NCT03569293
Trial related presentations / publications
Mendes-Bastos P, Ladizinski B, Guttman-Yassky E, Jiang P, Liu J, Prajapati VH, Simpson EL, Vigna N, Teixeira HD, Barbarot S. Characterization of acne associated with upadacitinib treatment in patients with moderate-to-severe atopic dermatitis: A post hoc integrated analysis of 3 phase 3 randomized, double-blind, placebo-controlled trials. J Am Acad Dermatol. 2022 Oct;87(4):784-791. doi: 10.1016/j.jaad.2022.06.012. Epub 2022 Jun 15.
Simpson EL, Papp KA, Blauvelt A, Chu CY, Hong HC, Katoh N, Calimlim BM, Thyssen JP, Chiou AS, Bissonnette R, Stein Gold LF, Wegzyn C, Hu X, Liu M, Liu J, Tenorio AR, Chu AD, Guttman-Yassky E. Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical Trials. JAMA Dermatol. 2022 Apr 1;158(4):404-413. doi: 10.1001/jamadermatol.2022.0029.
Guttman-Yassky E, Teixeira HD, Simpson EL, Papp KA, Pangan AL, Blauvelt A, Thaci D, Chu CY, Hong HC, Katoh N, Paller AS, Calimlim B, Gu Y, Hu X, Liu M, Yang Y, Liu J, Tenorio AR, Chu AD, Irvine AD. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials. Lancet. 2021 Jun 5;397(10290):2151-2168. doi: 10.1016/S0140-6736(21)00588-2. Epub 2021 May 21. Erratum In: Lancet. 2021 Jun 5;397(10290):2150. doi: 10.1016/S0140-6736(21)01214-9.
Public notes

Contacts
Principal investigator
Name 0 0
ABBVIE INC.
Address 0 0
AbbVie
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT03569293